Qiagen N.V. (QGEN) – What Are Brokerages Saying About This Stock?

Shares of Qiagen N.V. (NYSE:QGEN) have received a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. Eleven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $44.43.

A number of equities research analysts have recently weighed in on the stock. Citigroup restated a “neutral” rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. UBS Group initiated coverage on shares of Qiagen in a research report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 price objective for the company. DZ Bank downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Robert W. Baird increased their target price on Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Weiss Ratings upgraded Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 11th.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Amundi boosted its holdings in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after buying an additional 524,959 shares in the last quarter. State Street Corp lifted its position in Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after purchasing an additional 93,575 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Qiagen by 20.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock valued at $66,649,000 after buying an additional 286,665 shares during the period. Swiss National Bank boosted its position in shares of Qiagen by 21.1% during the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock worth $28,686,000 after purchasing an additional 124,920 shares in the last quarter. Finally, Arbejdsmarkedets Tillaegspension boosted its holdings in Qiagen by 24.8% during the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock worth $25,502,000 after buying an additional 126,405 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Price Performance

Qiagen stock opened at $50.42 on Wednesday. The firm has a market cap of $10.39 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 5.01 and a beta of 0.61. The company’s 50 day moving average is $44.44 and its two-hundred day moving average is $40.64. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the previous year, the firm posted $0.60 EPS. Qiagen’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, research analysts expect that Qiagen will post 2.44 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.